Neuroblastoma is among the most aggressive tumors that occur in childhood and infancy. The clinical prognosis of children with advanced-stage neuroblastoma is still poor. Interleukin-24 (IL-24) is emerging as a new cytokine involved in tumor cellular proliferation, differentiation, and apoptosis and has been widely studied as a tumor inhibitor. However, little is known about this cytokine's role in neuroblastoma. In this study, we investigated the possible effects of IL-24 on inducing neuroblastoma cell differentiation, growth inhibition, and apoptosis in vitro. Our data show that IL-24 promotes neuroblastoma SH-SY5Y cell differentiation, growth inhibition, and apoptosis. Furthermore, we found that the differentiation- and apoptosis-inducing action of IL-24 depends on the accumulation of reactive oxygen species (ROS). These results suggest that IL-24 can induce neuroblastoma cell differentiation and apoptosis and may be a potential therapeutic agent for neuroblastoma.
Get full access to this article
View all access options for this article.
References
1.
BautersTG, LaureysG, Van de VeldeV, BenoitY, RobaysH. 2011. Practical implications for the administration of 13-cis retinoic acid in pediatric oncology. Int J Clin Pharm, 33,4:597–598.
2.
CaudellEG, MummJB, PoindexterN, EkmekciogluS, MhashilkarAM, YangXH, RetterMW, HillP, ChadaS, GrimmEA. 2002. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol, 168,12:6041–6046.
3.
CheungR. 2012. Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: A US SEER Data Analysis. Asian Pac J Cancer Prev, 13,9:4587–4591.
4.
DashR, BhutiaSK, AzabB, SuZZ, QuinnBA, KegelmenTP, DasSK, KimK, LeeSG, ParkMA, YacoubA, RahmaniM, EmdadL, DmitrievIP, WangXY, SarkarD, GrantS, DentP, CurielDT, FisherPB. 2010. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev, 21,5:381–391.
5.
DE IorisMA, ContoliB, JenknerA, DE PasqualeMD, SerraA, DE SioL, PessolanoR, GarganeseMC, CrocoliA, CorneliT, BoldriniR, CastellanoA. 2012. Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma. Anticancer Res, 32,12:5527–5533.
6.
DentP, YacoubA, HamedHA, ParkMA, DashR, BhutiaSK, SarkarD, WangXY, GuptaP, EmdadL, LebedevaIV, SauaneM, SuZZ, RahmaniM, BroaddusWC, YoungHF, LesniakMS, GrantS, CurielDT, FisherPB. 2010. The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther, 128,2:375–384.
7.
FinkelT. 1999. Signal transduction by reactive oxygen species in non-phagocytic cells. J Leukoc Biol, 65,3:337–340.
8.
HobbieWL, MoabSM, CarlsonCA, GruccioD, GinsbergJP. 2011. Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma. Pediatr Blood Cancer, 56,3:474–476.
9.
HuangEY, MadireddiMT, GopalkrishnanRV, LeszczynieckaM, SuZ, LebedevaIV, KangD, JiangH, LinJJ, AlexandreD, ChenY, VozhillaN, MeiMX, ChristiansenKA, SivoF, GoldsteinNI, MhashilkarAB, ChadaS, HubermanE, PestkaS, FisherPB. 2001. Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties. Oncogene, 20,48:7051–7063.
10.
JiangH, LinJJ, SuZZ, GoldsteinNI, FisherPB. 1995. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene, 11,12:2477–2486.
11.
KhandrikaL, KumarB, KoulS, MaroniP, KoulHK. 2009. Oxidative stress in prostate cancer. Cancer Lett, 282,2:125–136.
12.
LebedevaIV, SuZZ, VozhillaN, ChatmanL, SarkarD, DentP, AtharM, FisherPB. 2008. Mechanism of in vitro pancreatic cancer cell growth inhibition by melanoma differentiation-associated gene-7/interleukin-24 and perillyl alcohol. Cancer Res, 68,18:7439–7447.
13.
LevN, MelamedE, OffenD. 2006. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett, 399,1–2:27–32.
14.
MargueC, KreisS. 2010. IL-24: physiological and supraphysiological effects on normal and malignant cells. Curr Med Chem, 17,29:3318–3326.
15.
MarisJM. 2010. Recent advances in neuroblastoma. N Engl J Med, 362,23:2202–2211.
16.
MatthayKK, ReynoldsCP, SeegerRC, ShimadaH, AdkinsES, Haas-KoganD, GerbingRB, LondonWB, VillablancaJG. 2009. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol, 27,7:1007–1013.
17.
NittiM, FurfaroAL, TraversoN, OdettiP, StoraceD, CottalassoD, PronzatoMA, MarinariUM, DomenicottiC. 2007. PKC delta and NADPH oxidase in AGE-induced neuronal death. Neurosci Lett, 416,3:261–265.
18.
ParkMA, YacoubA, SarkarD, EmdadL, RahmaniM, SpiegelS, KoumenisC, GrafM, CurielDT, GrantS, FisherPB, DentP. 2008. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy, 4,4:513–515.
19.
PataerA, ChadaS, RothJA, HuntKK, SwisherSG. 2008. Development of Ad-mda7/IL-24-resistant lung cancer cell lines. Cancer Biol Ther, 7,1:103–108.
20.
SarkarD, LebedevaIV, GuptaP, EmdadL, SauaneM, DentP, CurielDT, FisherPB. 2007. Melanoma differentiation associated gene-7 (mda-7)/IL-24: a ‘magic bullet’ for cancer therapy?Expert Opin Biol Ther, 7,5:577–586.
21.
SauerH, WartenbergM, HeschelerJ. 2001. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem, 11,4:173–186.
22.
SchorNF. 1999. Neuroblastoma as a neurobiological disease. J Neurooncol, 41,2:159–166.
23.
TongAW, NemunaitisJ, SuD, ZhangY, CunninghamC, SenzerN, NettoG, RichD, MhashilkarA, ParkerK, CoffeeK, RameshR, EkmekciogluS, GrimmEA, van Wart HoodJ, MerrittJ, ChadaS. 2005. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther, 11,1:160–172.
24.
TsukagoshiH, BuschW, BenfeyPN. 2010. Transcriptional regulation of ROS controls transition from proliferation to differentiation in the root. Cell, 143,4:606–616.
25.
VillablancaJG, KhanAA, AvramisVI, SeegerRC, MatthayKK, RamsayNK, ReynoldsCP. 1995. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol, 13,4:894–901.
26.
YanS, ZhangH, XieY, ShengW, XiangJ, YeZ, ChenW, YangJ. 2010. Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo. Cancer Invest, 28,1:85–93.
27.
YangBX, DuanYJ, DongCY, ZhangF, GaoWF, CuiXY, LinYM, MaXT. 2011. Novel functions for mda-7/IL-24 and IL-24 delE5: regulation of differentiation of acute myeloid leukemic cells. Mol Cancer Ther, 10,4:615–625.
28.
ZhengM, BocangelD, RameshR, EkmekciogluS, PoindexterN, GrimmEA, ChadaS. 2008. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther, 7,12:3842–3851.
